Clinical Trial Update: Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction [Phase 3]

View source ↗

Summary

Phase 3 open-label extension evaluating long-term efficacy and safety of LIB003 in patients with homozygous and heterozygous familial hypercholesterolemia and h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Familial Hypercholesterolemia
• Hypercholesterolemia

Drugs mentioned

• LIB003

Snippet

Sponsor: LIB Therapeutics LLC | Conditions: Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol | Phase 3 | Status: ENROLLING_BY_INVITATION